Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good afternoon, everybody. My name is Hannu Martola, and I'm the president and CEO of Detection Technology. Welcome to Detection Technology's second quarter results webcast. I'm here to announce our results through this webcast. But before starting, just briefly, what does Detection Technology do? We are the eyes of X-ray equipment. We provide our detectors to major medical, security, and industrial OEMs. You can find our products in hospitals in computed tomography equipment, at airports for security screening, and in various industrial applications, such as battery manufacturing or food scanning for manufacturing lines, and so on. I'm pleased to now report what we have achieved after the second quarter and during the second quarter. We reached the sales of €26.1 million, growing about 4%, up from 3.5% last year. In the second quarter, we reached much better profitability, at €3.3 million, which is 12.7% of our second-quarter sales. We had quite a big variation in our business units. Our industrial business unit grew really nicely by 43%. The majority of that growth is coming from a new acquisition. We acquired Hubble and their flat panels, but also, our industrial business unit grew nicely without them. There's now, like food, industrial and so on. The various industrial markets have returned to small growth in this business. However, medical sales were a disappointment, but as expected, the healthcare sector has not been very strong. Especially in China, the healthcare reform, which has been affecting the medical sales there, was still limiting the sales. However, we have now started to see some very small positive market signals, and we expect that medical will start to slowly recover. Security sales were nice at 27%. As a big business unit, it contributes significantly to our 3.5% growth. Sales were growing in all areas, especially aviation, for security screening applications. We improved quite consistently, our year-over-year result; cash flow was really strong. And what I think is very nice, is that this is the fifth consecutive quarter that the earnings have improved for Detection Technology. On net sales by quarter, slightly better than last year. We guided flat, so this is a flat plus. So, 3.5% is still above the zero level. And actually, we have to go back to 2019 since we have had this level of sales for the second. For the second quarter on EBIT, a clear step from a year-on-year numbers. Actually, in the company, we are quite pleased with this result. I think it was as expected but slightly better than expected. But we also have to note that this 12.7 is still below the midterm target that we have set, which is 15%. But for the second quarter, the sales and results were quite acceptable. By business unit: Security has now become the largest business unit of Detection Technology, representing about 44% of our total sales, followed by medical, which after a decline, accounts for 36%. And industrial now constitutes one fifth or 20% of our sales. On markets, we clearly grew in Europe, the Middle East, and Africa, largely driven by demand in security. So, there was a 56% year-on-year growth. Conversely, the Americas experienced a significant decline. There were some exceptional items that affected the Americas' sales. In the Asia Pacific, the sales were very much the same as last year, comprising 6% of the total, a bit down from the previous year. Europe, the Middle East, Africa accounted for about 30% and the Americas for 6% of the total sales. Looking at the full year, the first half was roughly just shy of €50 million, or about flat compared to last year, with a 2% growth. We are looking forward to higher growth in the second half of the year, as we have expected and informed the markets. The EBITA is 11.4, which I think is a good start for the year. For the second half, we anticipate and should observe better performance. By business units: This trend is very similar to that of the first quarter. The medical sector was heavily down due to the China healthcare reform and anti-corruption campaigns. Both the IBU and SBU saw nice growth of over 20%. By region, the Americas were down by 60%. However, Europe was up close to 40% and Asia Pacific was effectively flat, increasing by 3.2%. Regarding finances and key figures: Just a couple of items to note here. The R&D spending was about the same as last year at €3 million, constituting 11.7% of the budget. We had very nice cash flow. That amounted to €3.9 million and €6.8 million for the first half. Investments decreased after we finalized the clean room and other facilities. First half investments totaled €1.5 million, and out of that, the second quarter accounted for €350,000. Earnings per share stood at €0.15. Concerning strategy highlights: We have now finalized and established a subsidiary, a legal entity in India. We are building a service, manufacturing, and assembly site and center in India. We also finalized the old site and factory, ensuring we are now ready to make about 10% of our sales from that side during the second half. Furthermore, we continued launching a wide range of TFT panels from Harbor Imaging. That has gone as planned, including the new dynamic panels called IGZO panels. Many of the other events we have implemented include the target setting and KPI system within the company called OnePlus SCR, which is very similar to the known OKR system. Additionally, we are starting to use the sustainability reporting system called CSRD, which is due next year. Regarding sales expectations, for the industrial sector, we expect double-digit growth in the third quarter, medical to turn to slight growth after a somewhat disappointing first half, and security to also continue with double-digit growth. As a company, our full guidance is that we expect our total net sales to grow in double digits for the third quarter and also for the entire second half. Our financial targets remain the same, with at least a 10% annual growth and at least a 15% or better operating margin, EBITDA. Additionally, out of the net proceeds, dividends of 30% to 60% will be distributed. Despite some global challenges, our business outlook for the second half is quite positive, and we now expect the business to enter into double-digit growth. Although the healthcare sector in China, which is our main market, does not yet show clear signs of recovery, there are some initial signs of increasing orders and sales forecasts. The security and industrial areas, as previously mentioned, should continue to grow. This is, in a nutshell, what's currently happening. What did we accomplish in the second quarter? If there are any questions, I would be pleased to answer them.
Hi, it's Matrix Carnegie. A couple of questions to start with the US and Americas: you mentioned exceptional reasons why net sales there are down while they are up in Europe. Could you remind us what those exceptional reasons are? Are customers taking deliveries in other parts of the world?
Yes, the US is the world's largest market. And within the Americas, sales in the US are the most important. Even though we have some sales in South America, for example, there is very little manufacturing actually taking place in the US for most of the equipment; the special detectors are imported. But, as we measure and report our sales, it is based on where we ship and where we invoice. We have some fairly large customers in the US focused on one customer that is moving and they have built up some stock and there is some time before they start taking stock, and so on. So, this is the reason why I use the term 'exceptional'. The US and Americas sales, we believe, are now on a consecutive basis, will be improving for the third quarter and will continue improving into the fourth quarter, getting back to normal and also into the growth trajectory.
So what you're basically saying is that the growth in European sales is not just explained by weak US sales, but it's a case of US customers not taking deliveries at the moment, while others are doing quite well, actually.
Yes and no. Part of the sales growth in Europe, the Middle East, and Africa is actually going to the Americas, like the US market. So, both are true.
All right, thanks. Then, about the sales mix in Q2. Was it quite normal, or was it slightly better than you might expect? I mean, medical was quite a lot down. Others were up. So, was there something peculiar in the profitability?
I think the mix is what we've anticipated, of course, it's what you anticipate. But let's say, during the spring, at the beginning of the year, we would not have thought medical to go down by 25%. We knew that it was going down, maybe close to 20%, but it ended up being a little bit more. However, both security and especially industrial sectors performed better. We are quite pleased that now the industrial sector outside the harbor is also growing, and the markets are pulling.
But basically, the sales mix that you had does not explain in any way the margin development. So it would have been the same, even though the growth rates would have been much closer to each other. Is that right?
Well, the sales mix naturally always explains the margins because that's the source for the throughput and margins. But we have seen some fluctuation differences inside the business units, depending on the customers and which products we are selling. So there's more variance from that point of view, not just from the business unit itself.
I was just thinking, then, when you said that the demand for TFT flat panel detectors has been good, and since that is a new product for you, you might think that there would be some margin additions related to those revenue streams. So is that correct, or does it have the same profitability pattern as others? The older products.
I mean, the TFT flat-panel detectors are primarily going to industrial applications, like in China, and a little bit to medical and so on, on average. Actually, the margins are quite similar to the average margins for DT. But there are differences if you look at different applications like industrial and medical. Then if you look inside.
All right. And then in the industrial business, the growth rate was quite nice. While it was not nice in Q1, were there some exceptional circumstances in Q1, Q2 making it that good? So is it essentially something that you just happen to gather quite a lot of business in Q2, or is it something that could be replicated in the latter part of the year? I mean, do you still expect to have that kind of high growth rate going forward?
Well, the exception was a little bit in Q1. There was still some stock correction from last year and also the food industry, which is important for our legacy IBU, was not pulling, and now the full IBU, I think markets were more normalized than we expect these to continue. And that's why we believe the IBU will also be growing double-digit for the third quarter.
All right. Then finally, the subsidiary in Delhi. Could you describe a bit more what you are going to achieve there? So, what's the production capacity? Should it be somewhere similar to the entire auto factory amounting to 10% of your product sales, or is it larger than Hulu? And when will it be in use? And how much CapEx are you putting into it?
The India subsidiary, and the long-term bottom line is that India is significantly investing in infrastructure to support the country's development and growth. And that will mean a lot of investments also into security, healthcare, and industrial areas where X-ray technology is needed. From the Texas point of view. We have now established and founded a company in the New Delhi area, and we are taking it one step at a time. We are not planning to do anything massive. We are planning to do enough so that we can market and grow our sales there. At the beginning, we have a small assembly and assembly site. As we have assessed overall, there will not be a need for significant investments from today's perspective, but of course, we are continuing to monitor developments. And also, there might be some regulatory changes coming in there and so on. So we have to adapt based on the needs. The first step we want to take is to become a local player in India, meaning that we are making 'Made in India' products for the Indian markets. And then, we continue and grow the business according to the needs.
All right. That's all for me.
From CB. Starting with China and the business outlook there. So, how did that develop during Q2, compared to your expectations prior to the quarter?
Uh, I.
In the China market, for example, the security and industrial sectors performed as expected, while the medical side was somewhat less robust. Less than what we anticipated. Not very much. We expected the first and second quarters to be fairly low in Chinese healthcare.
Do you also share the view that the outlook now for China's medical sector for H2 is slightly weaker than what you would have expected at the beginning of the year?
I think the second half is still probably a bit challenging in China. It will most likely be there, showing some slight growth. But that is also due to the fact that the underlying quarters are quiet for everybody, are quite sort of lowish. And then, it is a general belief that 2025 will be very strong in China.
Okay. So do you expect that you could be able to grow also in Q4 in medical, even though the comparable will be more challenging than in Q4?
Yes. Our fourth quarter last year was a bit better due to some budget items in the market. Uh, so the fourth quarter was better than the third quarter last year. Uh, what I would rather say is that we look forward to the medical sector growing in the second half. Then how it's split between the quarters and so on. Uh, so we don't expect this kind of health care reform to deal out with a big bang or anything like that. It's sort of slow, let's say starting to recover slowly and then, uh, at an increasing pace, hopefully next year.
Understand? Uh, then were all of the cost savings already visible now, now in Q2 and then speaking of the Indian subsidiary. So how much will that increase your costs?
We, uh, we try to be, uh, tight with the costs and, uh, with the spending. I mean, the savings that we achieved during, like, last fall and so on. They are visible. They were visible in the first quarter. And now also for the second quarter and, uh, like I said, we don't plan to do anything really big at once in India. That would drive huge cost spending nor huge investments. We plan to take one step at a time and gradually increase. Or so we must remember that we will then get income from India and we already have some nice sales in India. And we expect that to grow. And then part of the things can be then paid with the deliverables from the sales.
Understand? Then the last one from me. Uh, there have been new liquid limits set in airports in Europe for safety detectors. Uh, due to some technical issues. So can you clarify what kind of issue this is? And are those problems related to your components and that lead to delays in investments in Europe.
Yeah. Thanks. So, uh, what the European Union actually announced, was it last Wednesday or Thursday that from the 1st of September, they have defined what is the maximum size of a single item, single pack of liquids in a bag. And the new definition is 100mm. One can have several of these items in a bag, but each item is a maximum of 100 millimeters. So before this, kind of like a definite specification did not exist, quite many airports, by the way, were using their own sort of restriction of 330 milliliters. And what we have understood is, this kind of scan to understand what's inside the liquid with computed tomography. Tomography is fairly complex. And it requires quite developed algorithms. To our understanding, after some tests, they found out that the results were not sufficient. Now, they have imposed temporary restrictions for the industry until the issues are resolved, which relates to the algorithms of the equipment, not to our or any of our competitors' detectors themselves. Everyone in the industry and anyone flying is restricted by these same requirements. We don't foresee that this will have any significant impact on the plans for installing CT equipment at airports. Purchasing new equipment is simply a new stipulation; the benefits of using CT are still evident. And the benefits are actually quite significant. Meaning, people can leave their laptops in, and their liquids, but only in containers of maximum 100ml. With these allowances at airports, it will mean faster passenger throughput and smoother operations. And actually, even better security at the airports.
So, you don't expect airports to wait for the issue to be resolved before investing in new equipment?
No, we don't think so. Well, it's temporary. It's temporary. We don't know for sure. I mean, even if it were permanent, in our opinion, it would not have a significant impact on the need for airports to renew their technology and for passengers to enjoy a more pleasant experience being checked with computed tomography.
All right, I understand. Thanks. That's all for me.
Hi. Walter Ross from Danske Bank. The first question is about TFT sales. You said that they soared in Q2. Can you give any kind of indication on the percentage of year-on-year growth or what kind of share of industrial sales they were? They were significant.
Well, the reason for the very nice industrial sales growth, 43%, is that we did not have any TFT sales in the underlying quarter of the previous year. So in Q2 2023, we took inventory into our books starting from the 1st of July. So, starting from the third quarter. And that explains the very nice 43% growth. The majority of the growth came from TFT panels, due to the reason I explained. But there is also significant growth in the legacy EBU part.
All right. But roughly, how much are TFT sales now as a share of the industrial segment's sales?
Well, we don't report it separately. And actually, part of the TFT sales is in the medical sector, and a minor part of the TFT sales is already going to medical, with the major part being industrial. What we are now working on is getting these TFT flat panel detectors approved by mid-sized and larger medical players, as well as dental players, and then that would yield higher growth, hopefully starting from late next year.
All right. Actually, my next question kind of relates to that. So you mentioned the TFT solutions for dental imaging now. But are there any other sales outside the industrial segment within TFT solutions?
There is. Well, dental is the most important for the medical sector. But there are also some other applications. And then, in the industrial area, there are various applications, one very interesting and exciting application for TFT flat panel detectors is battery manufacturing. So through the battery manufacturing process, starting from the minerals and raw materials to the battery cells, then to the battery modules, and even sorting of batteries and reusing the metals and precious materials. So X-rays are needed.
Okay. So currently, there are some sales in the medical sector already for TFT. But not in security, none at all. It's
Yeah. That’s interesting, actually, these TFT panels have almost no presence in security. It's, that's just how it is. There's very little application for flat panels in security lines.
Okay. Thanks. Then, regarding the medical segment's growth expectations, you say it's going to grow in H2. But, is it more likely to be low double-digit or higher rates? Any indication of that right now?
I mean, we cannot say for certain, but we believe that it's going to grow. How much time will then show? I mean, there are some small signals, like the China market, which is a global hub for healthcare equipment. So, it's very difficult to gauge, we have been quite actively talking to our customers in July. It seems that nobody has a clear view. And I understood also from the major healthcare players like General Electric, Siemens, Philips, and Canon, They are the four biggest. They also gave a similar message from their second-quarter results.
All right. Thanks. Then two quick ones still on SBU. Can you specify which markets specifically performed well or developed well in the West? In city upgrades? Any specific comments?
Europe and the U.S.
Okay. But within Europe, like uh.
I mean, there are various, I mean, I think there was one announced, airport by airport, one in Switzerland, and it was a major event. Overall, the markets are where the seats are installed. And we are actively involved in many of these areas. So we are market leaders in computed tomography.
All right then, maybe it's a bit of a broad question. But you also mentioned the accelerated growth in the global security market. Your view on that, uh, strengthened, uh, what are the specific reasons for that? What is driving your increased expectations there?
I think, uh, the big driver is when you watch the news. I'm sorry, but there are no financial webcast transcripts in your request to correct. There are a lot of concerns and a lot of things happening. Countries and governments aim to protect their citizens by employing various screening and scanning technologies, which typically involve the use of X-ray.
All right. Uh, from me.
I see iOS 11 from Apple. Well, you already kind of answered my question regarding the industrial segments Q2 growth rate, mainly, namely that the 43% growth was largely attributable to the BTS acquisition. But could you maybe still comment on the legacy business growth? I mean, what was the recovery like in the legacy business? Was it mainly driven by the food industry, which had been rather soft in past quarters?
Yeah.
I think, yes. I mean, the big change was, namely, especially in food. The IBU, the legacy as we call it, is a set of quite different applications. One of the major factors was food, particularly during the first quarter, where the notable exceptionality was that there was some stock correction and the markets did not behave as expected during 2023. And it yielded results, with end customers holding some stock. And that was corrected during the first quarter. So now the stocks are being used up. And uh, it's back to the sort of normal business. Hello everyone, thank you for joining us today for what promises to be an insightful presentation on Detection Technology's performance for the first half of the year 2024.
Thank you.
You walk in on an endless corridor. Plenty of questions have been asked, but I have a couple more. Firstly, about hyper data, it seems that you are kind of gaining traction there. And right now, is everything developing in order for your plan to work, for 2025 to get the medical approvals and, you know, the bigger industrial clients?
Yes, I think what is very important is the yield of new products that is going as planned. And then, the internal initiatives we are undertaking involve developing the team and training, as we have actually done in August. We have a large sales training, a global training for everyone. TFT technology and how to manage sales and account leadership effectively. So, these kinds of activities are ongoing and proceeding as planned. So if we look at the finances and so on, we are on track. So we are as we planned, and what was intended is now being executed and taking place.
If I remember correctly, you mentioned that your target is for high growth to outpace the market. I suppose that's still intact, but could you give us any more color on that? How is the crowd outlook for the coming year?
It's important to note that Harbour is still fairly small, which means that the percentages can show considerable variance.
Fair enough. You mentioned that in the third quarter you expect double-digit growth in the second half. You expected double-digit growth, but do you also expect double-digit growth in the fourth quarter?
We expect double-digit growth in the third quarter. And then the second half, the fourth quarter, is still a bit of a question as well. I mean, how is the China healthcare market developing and so on? So that remains to be seen. Visibility for the third quarter indicates that we are expecting double-digit growth, and we anticipate maintaining double-digit growth for the full second half. Thank you.
There is no material related to Carnegie in this session. However, we can explore information regarding Detection Technology's financial performance as discussed in the webcast. One question still regarding China. Um, if we exclude the medical business, which is in a somewhat non-standard situation in China. Did Chinese business grow in the industrial and security sectors together?
The thing is that PT has been very much growing with the pace of the Chinese economy growth in recent years. China has therefore been quite an important market for us. During this year, actually, the importance of Chinese growth impact to our overall growth has lessened. We have actually grown more in the Western markets.
But you're essentially saying that you still experienced growth in China.
We must remember that we didn't have the Harbo operations last year. Sales numbers for the second quarter are available now. So, that's a significant detail. Harbo, being a Chinese company, has a lot of sales in China until we then start to sell more of those products outside of China, too.
Right.
But like I said, the importance of China to our growth has lessened.
Okay, but would it be true that excluding Harbo's net sales contribution, the kind of organic growth or growth without Harbo would have still resulted in growth in China?
If I put it this way, if one takes out the Harbo sales from our second quarter, the sales in China decreased from last year.
Okay. Thank you. Nothing further.
Okay, thank you for your questions. Do we have any questions from the webcast or from online participants?
Are there no further questions online?
Yes, I think we are ready to conclude right on time, and I thank the audience and viewers for your interest and attention. I wish everybody a very nice week. Thank you.



















